Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Global collaboRAtion on CIC-DUX4, BCOR-CCN3, High-grade Undifferentiated Round Cell Sarcoma (URCS) Project

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Experimental study with biological material : case series review of clinical and histological data

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with undifferentiated round cell sarcomas treated from 01 January 1983 and all new patients will be included. - Clinical and outcome information available. - Histological slides/formalin-fixed paraffin-embedded tissue tumor blocks from archive available to perform the histology analysis/frozen tissue representative of the tumor available. Who Should NOT Join This Trial: - Diagnosis different from undifferentiated round cell sarcomas - Patient with no clinical or outcome information available Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients with undifferentiated round cell sarcomas treated from 01 January 1983 and all new patients will be included. * Clinical and outcome information available. * Histological slides/formalin-fixed paraffin-embedded tissue tumor blocks from archive available to perform the histology analysis/frozen tissue representative of the tumor available. Exclusion Criteria: * Diagnosis different from undifferentiated round cell sarcomas * Patient with no clinical or outcome information available

Treatments Being Tested

OTHER

data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue

Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution. Treatment, outcome, and prognostic factors will be related with the molecular re-classification.

Locations (1)

IRCCs Istituto Ortopedico Rizzoli
Bologna, BO, Italy